Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Tofacitinib

2

XVII.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

1
Last update : 30/12/2013
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist

Publications

Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis.
Annals of the rheumatic diseases 2016 Jun;75;1133-8 2016 Jun
Risk of tuberculosis reactivation with tofacitinib (CP-690550).
The Journal of infectious diseases 2012 Jun;205;1705-8 2012 Jun
Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.
The New England journal of medicine 2012 Aug 09;367;495-507 2012 Aug 09
Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
The New England journal of medicine 2012 Aug 09;367;508-19 2012 Aug 09

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies